Initiating Early Control of Migraine Pain and Associated Symptoms
Status:
Completed
Trial end date:
2020-03-23
Target enrollment:
Participant gender:
Summary
AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan,
which is being developed for the acute treatment of migraine with or without aura in adults.
AXS-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. This
study is designed to evaluate the efficacy and safety of AXS-07 compared to placebo.
This is a randomized, double-blind, single-dose, placebo-controlled trial. Subjects who
successfully complete the screening period and continue to meet all entry criteria will be
randomly assigned to take one dose of either AXS-07 or placebo upon the earliest onset of
migraine pain.